4 High-Growth GARP Stocks With Attractive PEG Ratios for 2026
These four GARP stocks combine discounted PEG ratios with strong growth potential, offering investors a balanced strategy for 2026.
IART - Integra LifeSciences Holdings Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.00
DETAILS
HIGH:
$12.00
LOW:
$12.00
MEDIAN:
$12.00
CONSENSUS:
$12.00
DOWNSIDE:
19.38%
Stock News
Integra LifeSciences (IART) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IART or MASI: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears
Integra LifeSciences NASDAQ: IART is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief executive officer, Chief Financial Officer Lea Knight said during a Bank of America med tech conference discussion hosted by analyst Rei Tan.
Integra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT.
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
PRINCETON, N. J. , May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT.
Integra (IART) Upgraded to Buy: What Does It Mean for the Stock?
Integra (IART) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript
Integra (IART) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.41 per share a year ago.
Integra LifeSciences Reports First Quarter 2026 Financial Results
PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026.
Integra LifeSciences Announces Leadership Transition
Stuart Essig Appointed as Integra's Next President and Chief Executive Officer Michael McBreen Appointed Chief Commercial Officer
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is This the Right Time to Hold IART Stock in Your Portfolio?
Integra shows growth promise from strong CSS demand and global expansion, but debt load and macro pressures raise concerns for investors.
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Price Targets
Integra LifeSciences price target lowered to $12 from $13 at Truist
$12.00
(was $11.01)
Richard Newitter
·
Truist Financial
Integra LifeSciences price target raised to $15 from $13 at Truist
$15.00
(was $14.76)
Truist Financial
BTIG Upgrades Integra LifeSciences (IART) to Neutral
$20.00
(was $17.43)
Ryan Zimmerman
·
BTIG
Integra LifeSciences price target lowered to $26 from $32 at Truist
$26.00
(was $24.59)
Richard Newitter
·
Truist Financial
Citi Downgrades Integra LifeSciences (IART) to Sell
$23.00
(was $25.42)
Joanne Wuensch
·
Citigroup
Integra LifeSciences downgraded to Sell from Neutral at BTIG
$22.00
(was $25.42)
Ryan Zimmerman
·
BTIG
Integra LifeSciences price target raised to $32 from $25 at Truist
$32.00
(was $29.84)
Richard Newitter
·
Truist Financial
Integra LifeSciences (IART) PT Lowered to $25 at Truist Securities
$25.00
(was $23.14)
Richard Newitter
·
Truist Financial
Integra LifeSciences price target lowered to $40 from $49 at JMP Securities
$40.00
(was $23.14)
David Turkaly
·
JMP Securities
Wells Fargo Downgrades Integra LifeSciences (IART) to Equal Weight
$25.00
(was $23.14)
Vik Chopra
·
Wells Fargo
Piper Sandler keeps Neutral on Integra after results, favors Conmed and Tandem
$50.00
(was $46.85)
Matt O'Brien
·
Piper Sandler
Piper Sandler Cuts Price Target For Integra Lifesciences As It Divests Wound Care Portfolio
$55.00
(was $56.53)
FY22 EPS
·
Piper Sandler
Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (NASDAQ: IART), Marinus (NASDAQ: MRNS) and ObsEva SA (NASDAQ: OBSV)
$86.00
(was $70.95)
Anthony Petrone
·
Jefferies
Integra LifeSciences price target raised to $74 from $68 at Wells Fargo
$74.00
(was $75.07)
Shagun Singh Chadha
·
RBC Capital
Integra LifeSciences (IART) PT Raised to $74 at Wells Fargo
$74.00
(was $75.07)
Larry Biegelsen
·
Wells Fargo